Recorded Presentations from the NCCN 2020 Virtual Congress: Hematologic Malignancies™
The treatment of hematologic malignancies has become increasingly complex as a result of the rapid pace and number of advances in the biology and treatment of hematologic malignancies and the numerous novel drugs that have been approved or are in development, many with novel mechanisms of action. Clinicians who manage patients with hematologic malignances are challenged to stay abreast of advances in the evolving diagnostic and treatment landscape to ensure optimal patient outcomes.
This program will focus on updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®); new, emerging and novel therapeutic agents; advances in cancer care; and the practical management of patients with hematologic malignancies.
This information was originally presented at the NCCN 2020 Virtual Congress: Hematologic Malignancies™ held on October 9-10, 2020.
Target Audience
This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.
Learning Objectives
The goal of the NCCN 2020 Virtual Congress: Hematologic Malignancies™ is to ensure that members of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other relevant health care professionals, have the knowledge and skills necessary to:
- Apply the current standards of oncology care and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to optimize the management of patients with various hematologic malignancies.
- Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with hematologic malignancies.
- Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with hematologic malignancies.
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
Full disclosure of faculty relationships will be made prior to the activity.
These activities are approved for AMA PRA Category 1 Credit™ for physicians and are also certified for credit for nurses, pharmacists, and other oncology professionals. Complete accreditation information is provided before each individual educational activity.
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari (Internet Explorer is no longer supported)
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader or other PDF reader software for certificate viewing/printing